MediciNova, Inc. (NASDAQ:MNOV) Director Yoshio Ishizaka acquired 5,000 shares of MediciNova stock in a transaction dated Monday, August 21st. The stock was purchased at an average price of $5.17 per share, with a total value of $25,850.00. Following the completion of the purchase, the director now owns 5,000 shares of the company’s stock, valued at $25,850. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Shares of MediciNova, Inc. (NASDAQ MNOV) traded up 3.56% on Thursday, hitting $5.23. The stock had a trading volume of 33,286 shares. MediciNova, Inc. has a 52-week low of $4.40 and a 52-week high of $7.78. The firm’s 50-day moving average price is $5.07 and its 200 day moving average price is $5.58. The firm’s market cap is $183.41 million.

TRADEMARK VIOLATION NOTICE: This article was first posted by Watch List News and is the property of of Watch List News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US and international copyright laws. The original version of this article can be read at https://www.watchlistnews.com/medicinova-inc-mnov-director-yoshio-ishizaka-buys-5000-shares-of-stock/1520990.html.

Large investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. boosted its stake in MediciNova by 1.0% in the second quarter. Vanguard Group Inc. now owns 1,197,716 shares of the biopharmaceutical company’s stock worth $6,300,000 after buying an additional 12,249 shares during the period. State Street Corp boosted its stake in MediciNova by 5.7% in the second quarter. State Street Corp now owns 467,451 shares of the biopharmaceutical company’s stock worth $2,458,000 after buying an additional 25,118 shares during the period. Northern Trust Corp boosted its stake in shares of MediciNova by 10.6% in the second quarter. Northern Trust Corp now owns 368,599 shares of the biopharmaceutical company’s stock valued at $1,939,000 after buying an additional 35,331 shares during the last quarter. TIAA CREF Investment Management LLC boosted its stake in shares of MediciNova by 7.2% in the second quarter. TIAA CREF Investment Management LLC now owns 90,295 shares of the biopharmaceutical company’s stock valued at $475,000 after buying an additional 6,035 shares during the last quarter. Finally, SG Americas Securities LLC boosted its stake in shares of MediciNova by 88.9% in the second quarter. SG Americas Securities LLC now owns 61,930 shares of the biopharmaceutical company’s stock valued at $326,000 after buying an additional 29,153 shares during the last quarter. 22.05% of the stock is currently owned by institutional investors.

About MediciNova

Medicinova, Inc is a biopharmaceutical company. The Company focuses on acquiring and developing small molecule therapeutics for the treatment of diseases with unmet medical needs and a commercial focus on the United States market. Its pipeline includes MN-166 (ibudilast), MN-001 (tipelukast), MN-221 (bedoradrine) and MN-029 (denibulin).

Receive News & Ratings for MediciNova Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MediciNova Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.